Trial reportHaematologica2015
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Trial report in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 6 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Analyzing the impact of subcutaneous injection needle, device, and administration characteristics on patient pain, anxiety, and safety: a systematic literature review.Drug delivery · 2026Pooled it
- Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.Advances in therapy · 2022Pooled it
- Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis.Drug design, development and therapy · 2019Pooled it
- Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.Nature communications · 2016Pooled it
- Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma.Nature communications · 2016Pooled it
- Pooled it
- Trial
- Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.Blood cancer journal · 2021Trial
- Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.Leukemia · 2019Trial
- Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.Leukemia · 2018Trial
- Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.Haematologica · 2016Trial
- Trial
- An Approach to Antibody-Mediated Rejection in Pediatric Liver Transplantation.Pediatric transplantation · 2026Review
- Response-adapted lenalidomide-dexamethasone (LenDex) intensification after CyBorD induction for transplant-eligible multiple myeloma: the PIANO study.Blood research · 2026Article
- Targeting the Ubiquitin-Proteasome System for Cancer.MedComm · 2025Review
- AP-1 inhibitor induces ferroptosis via the PI3K/AKT pathway in multiple myeloma cells.Heliyon · 2024Article
- Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation.JCO precision oncology · 2024Article
- Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis.Blood cancer journal · 2024Article
- Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians.Blood cancer journal · 2023Article
- Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1.Biomarker research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 14 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the impact of subcutaneous versus intravenous bortezomib in the MM5 trial of the German-Speaking Myeloma Multicenter Group which compared bortezomib, doxorubicin, and dexamethasone with bortezomib, cyclophosphamide, and dexamethasone induction therapy in newly diagnosed multiple myeloma. Based on data from relapsed myeloma, the route of administration for bortezomib was changed from intravenous to subcutaneous after 314 of 604 patients had been enrolled. We analyzed 598 patients who received at least one dose of trial medication. Adverse events were reported more frequently in patients treated with intravenous bortezomib (intravenous=65%; subcutaneous=56%, P=0.02). Rates of grade 2 or more peripheral neuropathy were higher in patients treated with intravenous bortezomib during the third cycle (intravenous=8%; subcutaneous=2%, P=0.001). Overall response rates were similar in patients treated intravenously or subcutaneously. The presence of International Staging System stage III disease, renal impairment or adverse cytogenetic abnormalities did not have a negative impact on overall response rates in either group. To our knowledge this is the largest study to present data comparing subcutaneous with intravenous bortezomib in newly diagnosed myeloma. We show better tolerance and similar overall response rates for subcutaneous compared to intravenous bortezomib. The clinical trial is registered at eudract.ema.europa.eu as n. 2010-019173-16.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.